Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19

University of Copenhagen

Status: Completed

Conditions: Type 2 Diabetes Mellitus

Treatments: Other: Placebo; Other: GIP; Other: GLP-2

Study type: Interventional

Funder types: Other

Identifiers

NCT03867656

KS-4-Diabetes-19

Details and patient eligibility

About

Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2 diabetes.

Enrollment: 10 patients

Sex: Male

Ages: 25 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male
• Age 25 to 70 years old.
• Type 2 diabetes.
• In Metformin or sulfonylureas

Exclusion criteria

• Treatment with other antidiabetics
• Osteopososis or gastrointestinal disease
• Smoking
• Long term steroid treatment
• Weight change more than 3 kg within the last 3 months.
• Overweight or intestinal surgery

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

10 participants in 3 patient groups, including a placebo group

GLP-2

Experimental group

Description:

Glucagon-like peptide 2

Treatment:

Other: GLP-2

GIP

Experimental group

Description:

Glucose-dependent insulinotropic polypeptide

Treatment:

Other: GIP

Placebo

Placebo Comparator group

Description:

Saline

Treatment:

Other: Placebo